GA Principles for the Modern OD -

Note About Obtaining Credit:

You must view the course in its entirety, whether attending in person or virtually.
You must stay logged in to the virtual course until the end of the program.

Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

Scroll back to top

Details

Overview
Treatments for geographic atrophy (GA) are expected to reach the market in the near future. A key practice for primary eye care providers will be identification of GA lesions prior to referral to a retina specialist for administration of therapy.
Join Program Chair Peter K. Kaiser, MD; Mark T. Dunbar, OD, FAAO; and Priya Sharma Vakharia, MD, for an in-depth discussion on GA and the most important data related to drug candidates in the pipeline.

This activity is supported by unrestricted educational grants from Iveric Bio and Carl Zeiss Meditec.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Summarize the prevalence of age-related macular degeneration and GA and define the burden of illness linked specifically to GA
- Comprehend and explain the pathogenesis of GA
- Describe GA disease detection and factors influencing progression
- Appraise the therapies targeting GA that have previously been explored
- Articulate the most important data related to drug candidates in the pipeline, with a special emphasis on those candidates furthest along in development
Accreditation
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 125093, is accredited by COPE for continuing education for optometrists. This course is approved for 1.5 hours of CE.
Course #: 81810-TD
Activity #: 125093
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Note About Obtaining Credit:
You must view the course in its entirety, whether attending in person or virtually.
You must stay logged in to the virtual course until the end of the program.
Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Peter K. Kaiser, MD
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Chaney Family Endowed Chair in Ophthalmology Research
Cole Eye Institute
Cleveland, OH

Mark T. Dunbar, OD, FAAO
Director of Optometric Services
Bascom Palmer Eye Institute
University of Miami School of Medicine
Miami, FL

Priya Sharma Vakharia, MD
Retina Vitreous Associates of Florida
Palm Harbor and St. Petersburg, FL

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Peter K. Kaiser, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie, AffaMed Therapeutics, Applied Genetic Technologies Corporation, Allegro, Allergan, Allgenesis, Alnylam Pharmaceuticals, Alzheon, Annexon Biosciences, AsclepiX Therapeutics, Aviceda, Bayer, Bausch + Lomb, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Coherus, Complement Therapeutics, DelSiTech, Dompé, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto Biotech, Galimedix, Glaukos, Innovent, iRenix, Iveric Bio, jCyte, Kanaph Therapeutics, Chengdu Kanghong Biotechnology, Kera Therapeutics, Kodiak Sciences, Kriya Therapeutics, LensGen, Nanoscope Therapeutics, Novartis, Ocugenix, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra Therapeutics, Omeros, Oxurion, Palatin, Regeneron, Regenxbio, Resonance Medicine, RetinaAI Medical AG, Retinal Sciences, Roivant, Samsung Bioepis, SGN Nanopharma, Stealth Biotherapeutics, Stuart, Sustained Nano Systems, Takeda, Théa Pharma, Unity Biotechnology, and 2020 Onsite. Stock/Shareholder: Allegro, Ocular Therapeutix, and Regenxbio.
Mark T. Dunbar, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Allergan, Carl Zeiss Meditec, Genentech, Reed Exibitions, Regeneron, and Tarsus. Consultant: Allergan, Avellino, Carl Zeiss Meditec, Genentech, Iveric Bio, Orasis Pharmaceuticals, Regeneron, and Visus. Speaker's Bureau: Allergan, Carl Zeiss Meditec, and Regeneron.
Priya Sharma Vakharia, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Bausch + Lomb, Genentech, Gyroscope Therapeutics, Notal Vision, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, Annexon, AsclepiX Therapeutics, Bayer, Chengdu Kanghong, Biotech (PANDA Trial stopped 04/2021), EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron Pharmaceuticals, RegenxBio, and Unity. Speaker's Bureau: Bausch + Lomb, Genentech, and Heidelberg Engineering. Stock/Shareholder: Network Eye and Quad-C/Prism Vision Group.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Iveric Bio, or Carl Zeiss Meditec.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 12/19/2022

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Title

Share on ReachMD